Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara White

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
JID Innovations : Skin Science From Molecules to Population Health|October 15, 2024
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension StudyCaroline J Stone, Geeta Ahuja, Lais Lopes Almeida Gomes, et al.
Drugs & Aging|March 16, 2006
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studiesMichael H Schiff, Elaine B Yu, Michael E Weinblatt, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2002
Deficient Smad7 expression: a putative molecular defect in sclerodermaChunming Dong, Shoukang Zhu, Tao Wang, et al.
Plos One|July 24, 2008
Type I interferon: potential therapeutic target for psoriasis?Yihong Yao, Laura Richman, Chris Morehouse, et al.
BMC Pulmonary Medicine|March 2, 2011
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthmaJoseph M Parker, Chad K Oh, Craig LaForce, et al.
ACR Open Rheumatology|March 11, 2025
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic SclerosisBarbara White, Daniel E Furst, Tracy M Frech, et al.
Arthritis and Rheumatism|May 30, 2009
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosusYihong Yao, Laura Richman, Brandon W Higgs, et al.
Human Genomics and Proteomics : HGP|October 16, 2010
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus ErythematosusYihong Yao, Brandon W Higgs, Chris Morehouse, et al.
Arthritis Research & Therapy|June 9, 2016
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose studyElena Schiopu, Soumya Chatterjee, Vivien Hsu, et al.
Annals of the Rheumatic Diseases|August 2, 2011
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathwayBrandon W Higgs, Zheng Liu, Barbara White, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
JID Innovations : Skin Science From Molecules to Population Health|October 15, 2024
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension StudyCaroline J Stone, Geeta Ahuja, Lais Lopes Almeida Gomes, et al.
Drugs & Aging|March 16, 2006
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studiesMichael H Schiff, Elaine B Yu, Michael E Weinblatt, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2002
Deficient Smad7 expression: a putative molecular defect in sclerodermaChunming Dong, Shoukang Zhu, Tao Wang, et al.
Plos One|July 24, 2008
Type I interferon: potential therapeutic target for psoriasis?Yihong Yao, Laura Richman, Chris Morehouse, et al.
BMC Pulmonary Medicine|March 2, 2011
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthmaJoseph M Parker, Chad K Oh, Craig LaForce, et al.
ACR Open Rheumatology|March 11, 2025
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic SclerosisBarbara White, Daniel E Furst, Tracy M Frech, et al.
Arthritis and Rheumatism|May 30, 2009
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosusYihong Yao, Laura Richman, Brandon W Higgs, et al.
Human Genomics and Proteomics : HGP|October 16, 2010
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus ErythematosusYihong Yao, Brandon W Higgs, Chris Morehouse, et al.
Arthritis Research & Therapy|June 9, 2016
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose studyElena Schiopu, Soumya Chatterjee, Vivien Hsu, et al.
Annals of the Rheumatic Diseases|August 2, 2011
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathwayBrandon W Higgs, Zheng Liu, Barbara White, et al.
Pageof 8